Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CymaBay Therapeutics (CBAY)
NASDAQ:CBAY
RESEARCH TOOLSreports
Holding CBAY?
Track your performance easily
CBAY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.26 - $32.50
Previous Close$32.48
Volume0.00
Average Volume (3M)4.05M
Market Cap
$3.73B
Enterprise Value$3.33B
Total Cash (Recent Filing)$394.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 09, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding114,724,381
10 Day Avg. Volume2,903,629
30 Day Avg. Volume4,045,336
Standard Deviation0.27
R-Squared0.00395
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)12.74
Price to Sales (P/S)65372.77
Price to Cash Flow (P/CF)-34.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue107.29
Enterprise Value/Gross Profit107.29
Enterprise Value/Ebitda-35.62
Forecast
1Y Price Target
$32.50Price Target Upside― Upside
Rating ConsensusHold
Number of Analyst Covering11
CymaBay Therapeutics News
PremiumCompany Announcements
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul
PremiumCompany Announcements
CymaBay Therapeutics Revamps Executive Compensation Agreements
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CBAY FAQ
What was CymaBay Therapeutics’s price range in the past 12 months?
CymaBay Therapeutics lowest stock price was $7.26 and its highest was $32.50 in the past 12 months.
What is CymaBay Therapeutics’s market cap?
Currently, no data Available
When is CymaBay Therapeutics’s upcoming earnings report date?
CymaBay Therapeutics’s upcoming earnings report date is May 09, 2024 which is 202 days ago.
How were CymaBay Therapeutics’s earnings last quarter?
CymaBay Therapeutics released its earnings results on Feb 28, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.311 by -$0.039.
Is CymaBay Therapeutics overvalued?
According to Wall Street analysts CymaBay Therapeutics’s price is currently Undervalued.
Does CymaBay Therapeutics pay dividends?
CymaBay Therapeutics does not currently pay dividends.
What is CymaBay Therapeutics’s EPS estimate?
CymaBay Therapeutics’s EPS estimate is -$0.32.
How many shares outstanding does CymaBay Therapeutics have?
CymaBay Therapeutics has 68,701,000 shares outstanding.
What happened to CymaBay Therapeutics’s price movement after its last earnings report?
CymaBay Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.311. Following the earnings report the stock price went down -0.248%.
Which hedge fund is a major shareholder of CymaBay Therapeutics?
Among the largest hedge funds holding CymaBay Therapeutics’s share is RA Capital Management. It holds CymaBay Therapeutics’s shares valued at 164M.
---
CymaBay Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$32.50 (― Upside)
$32.50 (― Upside)
Blogger Sentiment
Bullish
CBAY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 922.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $986.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.47%
12-Months-Change
Fundamentals
Return on Equity
-64.17%
Trailing 12-Months
Asset Growth
206.44%
Trailing 12-Months
Company Description
CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
---
CBAY Earnings Call
Q3 2023
0:00 / 0:00
---
CBAY Stock 12 Month Forecast
Average Price Target
―Achieve Life Sciences
―
Eloxx Pharmaceuticals
―
Evoke Pharma
―
Galectin Therapeutics
―
Best Analysts Covering CBAY
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+141.10%
initiated a buy rating a year ago
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +141.10% per trade.
---